Relapsed or Refractory Acute Myeloid Leukemia
15
4
4
2
Key Insights
Highlights
Success Rate
22% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
46.7%
7 terminated out of 15 trials
22.2%
-64.3% vs benchmark
13%
2 trials in Phase 3/4
200%
4 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (15)
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)
AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia
A Study to Evaluate MK-0482 for Relapsed/Refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML) (MK-0482-002)
Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia
A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma or Chronic Lymphocytic Leukemia
Study of AMG 330 in Combination With Pembrolizumab in Adult With Relapsed or Refractory Acute Myeloid Leukemia
A China Bridging Study of Ivosidenib in r/r AML Subjects With an IDH1 Mutation
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PHI 101 for the Treatment of AML
CD123 Redirected Autologous T Cells for AML
Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia